Menu
1 min read · estimated
APPROVED USE
What FDA approved
Adults with metastatic non-small cell lung cancer with a RET gene fusion.
LAMPGEN ANALYSIS
Why it matters
Introduced a selective RET inhibitor for RET fusion-positive lung cancer under accelerated approval.
What research teams should watch
Use fusion-capable molecular testing and monitor blood pressure and liver tests during treatment.
PRIMARY RECORDS